These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25509897)

  • 1. [The problem of viral hepatitis C in the Russian Federation].
    Iushchuk ND; Znoĭko OO; Dudina KR; Belyĭ PA
    Ter Arkh; 2014; 86(10):77-81. PubMed ID: 25509897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The burden of viral hepatitis in the Russian Federation requires reducing its progression for the long term, including chronic hepatitis C)].
    Iushchuk ND; Znoĭko OO; Iakushechkina NA; Zyrianov SK; Shut'ko SA; Belyĭ PA; Kozina AN; Chapurin SA; Churilin IuIu; Lugovskikh EA
    Ter Arkh; 2013; 85(12):79-85. PubMed ID: 24640674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CLINICAL AND ECONOMIC ANALYSIS OF ALTERNATIVE SCHEMES OF ANTIVIRAL THERAPY OF CHRONIC HEPATITIS C GENOTYPE 1 IN PATIENTS WHO DID NOT ANSWER TO THE PRIOR THERAPY, IN THE RUSSIAN FEDERATION].
    Pyadushkina EV; Avxentyeva MV; Omelyanovsky VV; Khachatryan GR
    Eksp Klin Gastroenterol; 2015; (3):55-65. PubMed ID: 26281179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Socio-economic aspects of neurogenic dysfunctions in urology].
    Kasyan GR; Dreval RO; Krivoborodov GG; Gadzhieva ZK; Salyukov RV; Stroganov RV; Shipitsyn VV
    Urologiia; 2020 Nov; (5):127-132. PubMed ID: 33185360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
    Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC
    J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
    Cammà C; Petta S; Cabibbo G; Ruggeri M; Enea M; Bruno R; Capursi V; Gasbarrini A; Alberti A; Craxì A;
    J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [METHODOLOGICAL APPROACHES TO THE CALCULATION OF ACTUAL AND PREVENTED AS A RESULT OF CONTROL AND SUPERVISORY ACTIVITIES, MEDICAL-DEMOGRAPHIC AND ECONOMIC LOSSES, ASSOCIATED WITH THE NEGATIVE IMPACT OF ENVIRONMENTAL FACTORS].
    Popova AY; Zaytseva NV; May IV; Kir'yanov DA
    Gig Sanit; 2015; 94(7):95-9. PubMed ID: 26856152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Epidemiologic and situational panorama of hepatitis C in Mexico].
    Vera de León L; Juárez Navarro JA; Díaz Gómez M; Méndez Navarro J; Chirino Sprung RA; Dehesa Violante M; Casillas Davila L; Rizo Robles MT; Torres Ibarra R; Cano Domínguez C; Nava Estrada J; Ramos Gómez M; Hernández ME; Wong González S; Félix Tamayo M; Corona Lechuga Mdel C; Zárate Negrete AR; Rangel Jiménez M; Rodríguez Hernández H; González Ortiz V; Tirado Estrella MP; Villanueva Carreto ML; Orta Flores R; Manteca Argumedo JL; Vázquez Avila I; González Macias J; Razcón Hernández O; Torres López P; Bazán Pérez C
    Rev Gastroenterol Mex; 2005; 70(1):25-32. PubMed ID: 16170959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Social and economic burden of stroke in Russian Federation].
    Ignatyeva VI; Voznyuk IA; Shamalov NA; Reznik AV; Vinitskiy AA; Derkach EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(8. Vyp. 2):5-15. PubMed ID: 37682090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.
    Cammà C; Petta S; Enea M; Bruno R; Bronte F; Capursi V; Cicchetti A; Colombo GL; Di Marco V; Gasbarrini A; Craxì A;
    Hepatology; 2012 Sep; 56(3):850-60. PubMed ID: 22454336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance.
    Chevaliez S
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S46-51. PubMed ID: 22248694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
    Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
    Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic hepatitis C infection--eradication of the virus].
    Ben Ari Z
    Harefuah; 2014 Jul; 153(7):392-3, 433. PubMed ID: 25189028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sanitary and epidemiological well-being in children and adolescents: state-of-the-art and ways of solving the problem].
    Onishchenko GG
    Gig Sanit; 2007; (4):53-9. PubMed ID: 17729447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The current problems in the epidemiology and prevention of viral hepatitis B and C in the Russian Federation].
    Onishchenko GG; Shakhgil'dian IV
    Zh Mikrobiol Epidemiol Immunobiol; 2000; (1):50-4. PubMed ID: 10876894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
    Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
    J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.